| |
Audit
|
Nominating and Governance
|
Compensation
|
Paul Goddard Ph.D.
|
|
|
|
Chairman & Chief Executive Officer Dr. Goddard has served as the chairman of our board of directors since August 2003 and was appointed our chief executive officer in April 2005. From March 2000 and August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc., a pharmaceutical company, and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., the largest division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the board of directors of A.P. Pharma, Inc., Adolor Corporation, a biopharmaceutical company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company.
|
|
Peter G. Milner M.D.
|
|
|
|
President Dr. Milner is our co-founder and has served as president, research and development, since April 2005 and a member of our board of directors since February 1997. Dr. Milner is a board certified physician and cardiologist, and serves as voluntary clinical faculty at Stanford Veterans' Hospital. In June 1992, Dr. Milner co-founded CV Therapeutics, Inc., a biopharmaceuticals company. Prior to CV Therapeutics, Inc., Dr. Milner was an assistant professor of medicine at Washington University in St. Louis, Missouri. Dr. Milner has numerous patents in his name and is the author of several scientific articles published in peer-reviewed journals. Dr. Milner attended the University of Liverpool, England where he received a bachelor of sciences degree with honors in biochemistry and a degree in medicine. He completed his postgraduate training in medicine at Johns Hopkins Medical School, cardiology and pharmacology at University of Virginia and molecular biology at Washington University in St. Louis. Dr. Milner is a Fellow of the American College of Cardiology, serves on the board of directors of California Healthcare Institute and the Scientific Advisory Board of Novartis Institute of Biomedical Research in Cambridge, Massachusetts.
|
Rob Adelman M.D.
|
|
|
|
|
Dr. Adelman has served as a member of our board of directors since July 2002. Since March 2002, Dr. Adelman has worked at OrbiMed Advisors, LLC, a venture capital firm, where he is a private equity partner and focuses on private equity investments and structured transactions of small-capitalization public equity companies. In addition, Dr. Adelman was a founder of Sientra, Inc., an aesthetics company, and Veritas Medicine, Inc., a clinical trials patient recruitment company. He was also a co-founder of Operon Technology, Inc., a biotechnology company, now owned by QIAGEN N.V., a biotechnology company. Dr. Adelman trained as an orthopedic surgeon at the Hospital for Special Surgery at Cornell University and received his bachelor of arts degree from the University of California, Berkeley, and his doctorate of medicine degree from Yale University School of Medicine.
|
|
Lars Ekman M.D., Ph.D.
|
|
|
|
|
Dr. Ekman has served as a member of our board of directors since November 2003. Dr. Ekman is the executive vice president and president, global R&D and corporate strategy of Elan Corporation plc. Prior to joining Elan, he served as executive vice president, R&D, at Schwarz Pharma AG, a pharmaceutical company. Dr. Ekman has also served in a variety of senior scientific and clinical functions at Pharmacia Corp., which was acquired by Pfizer, Inc., a pharmaceutical company. Dr. Ekman is a board certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his doctorate degree and doctorate of medicine degree from the University of Gothenburg, Sweden.
|
|
Keith R. Leonard M.B.A.
|
|
|
|
|
Mr. Leonard has served as a member of our board of directors since September 2005. Since August 2005, Mr. Leonard has served as president and chief executive officer of Kythera Biopharmaceuticals, a biopharmaceutical company. From October 1991 to November 2004, Mr. Leonard held various positions with Amgen, Inc., a biopharmaceutical company, and its affiliates, most recently as senior vice president and general manager of Amgen Europe. Mr. Leonard holds a master of business administration from The Anderson School of Management, University of California, Los Angeles, a master of science in mechanical engineering from University of California, Berkeley, a bachelor of arts in history from University of Maryland, College Park, and a bachelor of science in engineering from University of California, Los Angeles.
|
|
Nick Simon M.B.A.
|
|
|
|
|
Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including its vice president of business and corporate development. Mr. Simon is currently on the board of directors of Sientra, Inc., and several pharmaceutical companies: Barrier Therapeutics, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.
|
|
Paul Sekhri
|
|
|
|
|
Mr. Sekhri has served as a member of our board of directors since September 2004. Since December 2004, Mr. Sekhri has served as president and chief executive officer of Cerimon Pharmaceuticals, Inc., a biopharmaceutical company. From October 2003 to December 2004 he served as president and chief business officer of ARIAD Pharmaceuticals, Inc., an oncology company. From December 2002 to September 2003, Mr. Sekhri was a partner at the Sprout Group, a venture capital affiliate of Credit Suisse, a financial services institution. From August 1999 to January 2003, Mr. Sekhri held various positions with Novartis Pharma AG, a pharmaceutical company, most recently as its senior vice president and head of global search and evaluation. Mr. Sekhri received his M.Sc. and B.Sc. from the University of Maryland.
|
|
Herm Rosenman M.B.A., C.P.A.
|
|
|
|
|
Mr. Rosenman has served as a member of our board of directors since January 2006. Since June 2001, Mr. Rosenman has served as the senior vice president of finance and chief financial officer of Gen-Probe Incorporated, a company that produces products for the clinical laboratory and blood screening. Mr. Rosenman received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. Mr. Rosenman serves on the board of directors of Infinity Pharmaceuticals, Inc., a biopharmaceuticals company.
|
Print page 
Email page 
Shareholder Briefcase
Printed Materials
Download Library
Glossary
RSS News Feeds
